IVI RMA Expands Fertility Care Across the Middle East

MADRID – (BUSINESS WIRE/AETOSWire) – IVI RMA Global, a world leader in reproductive medicine, has officially announced the Middle East as its newest operating region, following the completion of its acquisition of ART Fertility Clinics. ART Fertility operates in the United Arab Emirates and has strategic plans to expand into Saudi Arabia, strengthening IVI RMA’s footprint across the Gulf Cooperation Council (GCC) region.

The Middle East now joins IVI RMA’s existing operational regions, including North America, Italy, Northern Europe, and Iberia, Latam & Czechia. Under the guidance of ART Fertility Clinics CEO Suresh Soni and Medical Director Dr. Human M. Fatemi, IVI RMA will provide advanced fertility treatments to tens of thousands of patients across the region.

Recent World Bank data (2023) highlights a significant demographic shift in the Middle East, with declining fertility rates—1.2 births per woman in the UAE and steadily decreasing numbers in Saudi Arabia—indicating a growing need for fertility solutions.

“Across the Middle East, awareness of fertility challenges is increasing, and more couples are seeking advanced solutions daily,” said Dr. Fatemi. “As part of IVI RMA, we will expand our resources, accelerate scientific research, and elevate the standard of fertility care across the region.”

ART Fertility has earned recognition as a leader in the GCC, employing over 300 professionals, including world-renowned clinicians, embryologists, and geneticists. The clinic applies proprietary research, innovative protocols, and personalized treatment approaches, achieving industry-leading pregnancy rates of up to 71% across multiple age groups.

“The entire ART Fertility team is thrilled to join forces with IVI RMA,” said Mr. Soni. “Together, we will deliver greater value to our patients, enhance ongoing research, and continue advancing fertility science both in the Middle East and globally.”

In addition to exceptional patient care, ART Fertility has a strong focus on research and development, with over 268 peer-reviewed publications, 35 ongoing studies, and 11 hosted scientific conferences. Their research-driven approach aligns seamlessly with IVI RMA’s commitment to clinical excellence and innovation.

Javier Sánchez Prieto, CEO of IVI RMA Global, added, “We seek quality organizations that align with our standards and enhance our work. The Middle East presents growing demand for exceptional fertility care, and ART Fertility positions IVI RMA to lead the region while advancing global fertility science.”